Trial abstract · §3
ADJUNCT-TWO — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in glycated haemoglobin from baseline to week 26 with a capped insulin dose | Directionally consistent with ADJUNCT ONE | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Liraglutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 39.3 | 13.8 | SCALE Obesity (3.0 mg, 56 weeks) |
| Diarrhoea | 20.9 | 9.3 | SCALE Obesity |
| Constipation | 19.4 | 8.5 | SCALE Obesity |
| Vomiting | 15.7 | 3.9 | SCALE Obesity |
| Headache | 13.6 | 12.6 | SCALE Obesity |
| Cholelithiasis | 1.5 | 0.5 | SCALE Obesity |
| Acute pancreatitis | 0.3 | 0.1 | SCALE programme pooled |
| Discontinuation for adverse events | 9.9 | 3.8 | SCALE Obesity |
Compound Evidence Institute · CEI-TR-0077/3 · https://compoundevidence.com/trials/adjunct-two/results/ · retrieved 30 July 2026